Building a world where
tomorrow is another day!

サブ-ナビゲーション
  • Company
  • Science
  • News
  • Career
  • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

Home

News

  • Sep 15, 2023 Selected for the latest edition of "100 Amazing Venture Businesses" in 2023 pdf (184KB)
  • Sep 15, 2023 Nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2023 pdf (267KB)
  • Jun 01, 2023 Dosing of CLK Inhibitor CTX-712 Starts in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S. pdf (166KB)
  • May 17, 2023 Fujitsu, Kyoto University, and Chordia Therapeutics Launch AI Trials to Discover Biomarkers for New Cancer Drugs pdf (147KB)

View All

Science

Science

Science

Development Pipeline

Development Pipeline

CLK Inhibitor CTX-712

CLK Inhibitor CTX-712

MALT1 Inhibitor CTX-177

MALT1 Inhibitor CTX-177

CDK12 Inhibitor CTX-439

CDK12 Inhibitor CTX-439

GCN2 Inhibitor CRD-1968099

GCN2 Inhibitor CRD-1968099

View All

Company

Corporate Name Chordia Therapeutics Inc.
Foundation November 1, 2017
Head Office 26-1, Muraoka-Higashi 2-chome,Fujisawa, Kanagawa 251-0012 Japan MAP
Tokyo Office 3-11-5,Nihonbashi-honcho,Chuo-ku,Tokyo 103-0023 Japan
Representative Hiroshi Miyake, Ph.D. CEO

Mission

Message

Leadership
Team

Career

People

People

Contact

Contact

    マルチ3はありません

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box